Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Betta Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	414.33	471.68	752	731.28	791.99	1,346
Short-Term Investments	-	-	-	-	-	190
Trading Asset Securities	77.6	126.44	0.54	-	201.01	-
Cash & Short-Term Investments	491.93	598.12	752.54	731.28	993	1,536
Cash Growth	-39.74%	-20.52%	2.91%	-26.36%	-35.35%	194.64%
Accounts Receivable	324.19	98.47	286.41	450.62	173.38	52.61
Other Receivables	38.74	1.83	2.61	49.7	40.75	6.81
Receivables	362.93	100.3	289.02	500.32	214.13	59.42
Inventory	351.98	290.09	327.5	372.17	293.32	188.59
Prepaid Expenses	-	-	0.2	-	-	-
Other Current Assets	277.34	235.82	156.62	129.06	153.49	63.91
Total Current Assets	1,484	1,224	1,526	1,733	1,654	1,848
Property, Plant & Equipment	2,977	3,009	2,574	2,056	1,331	775.72
Long-Term Investments	1,730	1,437	1,382	919.27	345.79	274.55
Goodwill	413.58	413.58	413.58	413.58	413.58	413.58
Other Intangible Assets	2,710	2,776	1,944	1,219	1,183	603.37
Long-Term Deferred Tax Assets	58.57	56.73	39.13	85.96	55.06	55.22
Long-Term Deferred Charges	209.51	383.53	1,219	1,444	1,252	1,171
Other Long-Term Assets	115.85	41.99	50.3	39.3	37.6	87.79
Total Assets	9,699	9,342	9,147	7,910	6,271	5,230
Accounts Payable	750.68	746.11	800.12	35.85	431.19	113.62
Accrued Expenses	133.59	285.53	357.82	419.11	357.02	187.53
Short-Term Debt	105.09	100.08	300.27	380.39	-	-
Current Portion of Long-Term Debt	730.64	639.85	301.25	-	-	-
Current Portion of Leases	-	33.03	4.6	4.16	4.88	-
Current Income Taxes Payable	72.69	4.26	0.07	0.04	10.68	27.54
Current Unearned Revenue	2.17	2.63	4.92	4.46	0.69	1.27
Other Current Liabilities	132.31	36.47	34.11	1,261	84.4	108.14
Total Current Liabilities	1,927	1,848	1,803	2,105	888.86	438.1
Long-Term Debt	1,549	1,552	1,816	656.03	-	2.6
Long-Term Leases	75.65	71.63	8.18	7.3	6.34	-
Long-Term Unearned Revenue	192.7	150.99	144.7	112.76	112	58.01
Long-Term Deferred Tax Liabilities	35.76	53.49	23.39	71.57	68.39	64.64
Other Long-Term Liabilities	-	-	-	-	510.06	521.99
Total Liabilities	3,780	3,676	3,795	2,952	1,586	1,085
Common Stock	420.73	418.49	418.49	417.47	415.39	413.16
Additional Paid-In Capital	2,067	1,945	1,945	1,860	1,932	1,793
Retained Earnings	3,067	2,834	2,503	2,181	2,139	1,883
Comprehensive Income & Other	288.64	375.78	384.48	390.99	74.64	52.28
Total Common Equity	5,843	5,574	5,251	4,849	4,561	4,141
Minority Interest	76.16	92.3	100.4	108.64	124.9	3.41
Shareholders' Equity	5,920	5,666	5,351	4,958	4,686	4,144
Total Liabilities & Equity	9,699	9,342	9,147	7,910	6,271	5,230
Total Debt	2,460	2,396	2,430	1,048	11.22	2.6
Net Cash (Debt)	-1,968	-1,798	-1,678	-316.59	981.77	1,533
Net Cash Growth	-	-	-	-	-35.97%	-
Net Cash Per Share	-4.68	-4.29	-4.00	-0.76	2.36	3.77
Filing Date Shares Outstanding	420.73	418.49	418.49	417.47	415.39	413.16
Total Common Shares Outstanding	420.73	418.49	418.49	417.47	415.39	413.16
Working Capital	-442.98	-623.63	-277.28	-371.95	765.08	1,410
Book Value Per Share	13.89	13.32	12.55	11.62	10.98	10.02
Tangible Book Value	2,720	2,384	2,894	3,216	2,964	3,124
Tangible Book Value Per Share	6.46	5.70	6.92	7.70	7.14	7.56
Buildings	-	2,952	586.14	585.59	627.19	588.32
Machinery	-	449.64	424.26	402.25	376.01	339.24
Construction In Progress	-	191.87	2,037	1,448	639.67	63.12

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.